Health Care & Life Sciences » Pharmaceuticals | Durect Corp.

Durect Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
21,452.00
22,110.00
22,663.00
34,509.00
3,695.00
25,322
Depreciation, Depletion & Amortization
558.00
601.00
425.00
416.00
437.00
254
Other Funds
4,000.00
4,345.00
2,946.00
3,239.00
4,385.00
2,508
Funds from Operations
16,894.00
17,164.00
19,292.00
30,854.00
1,127.00
22,560
Changes in Working Capital
1,446.00
2,955.00
1,263.00
3,561.00
2,470.00
1,796
Net Operating Cash Flow
15,448.00
14,209.00
20,555.00
27,293.00
1,343.00
20,764
Capital Expenditures
69.00
204.00
225.00
147.00
69.00
Purchase/Sale of Investments
1,177.00
15,529.00
6,479.00
6,184.00
12,259.00
Net Investing Cash Flow
1,108.00
15,733.00
6,254.00
6,037.00
12,690.00
Issuance/Reduction of Debt, Net
9.00
19,769.00
261.00
1,078.00
14.00
Net Financing Cash Flow
10,981.00
24,786.00
15,204.00
23,077.00
12,624.00
Net Change in Cash
3,359.00
5,156.00
903.00
1,821.00
23,971.00
Free Cash Flow
15,517.00
14,413.00
20,780.00
27,440.00
1,412.00
Other Sources
-
-
-
-
500.00
Change in Capital Stock
10,990.00
5,017.00
15,465.00
24,155.00
12,638.00

About Durect

View Profile
Address
10260 Bubb Road
Cupertino California 95014
United States
Employees -
Website http://www.durect.com
Updated 07/08/2019
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. Its product pipeline consists of multiple investigational drug candidates in clinical development. It offers DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery; and REMOXY ER, which provides investigational extended release pain relief.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.